Alzheimer’s disease and specialized pro-resolving lipid mediators: Do MAR1, RVD1, and NPD1 show promise for prevention and treatment?

Research output: Contribution to journalReview article

Abstract

Alzheimer’s disease (AD) is a common neurodegenerative disease and a major contributor to progressive cognitive impairment in an aging society. As the pathophysiology of AD involves chronic neuroinflammation, the resolution of inflammation and the group of lipid mediators that actively regulate it—i.e., specialized pro-resolving lipid mediators (SPMs)—attracted attention in recent years as therapeutic targets. This review focuses on the following three specific SPMs and summarizes their relationships to AD, as they were shown to effectively address and reduce the risk of AD-related neuroinflammation: maresin 1 (MaR1), resolvin D1 (RvD1), and neuroprotectin D1 (NPD1). These three SPMs are metabolites of docosahexaenoic acid (DHA), which is contained in fish oils and is thus easily available to the public. They are expected to become incorporated into promising avenues for preventing and treating AD in the future.

Original languageEnglish
Article number5783
Pages (from-to)1-14
Number of pages14
JournalInternational journal of molecular sciences
Volume21
Issue number16
DOIs
Publication statusPublished - 2020 Aug 2

Keywords

  • Alzheimer’s disease
  • MaR1
  • NPD1
  • Neuroinflammation
  • Novel approaches
  • Resolution of inflammation
  • RvD1
  • SPMs

ASJC Scopus subject areas

  • Catalysis
  • Molecular Biology
  • Spectroscopy
  • Computer Science Applications
  • Physical and Theoretical Chemistry
  • Organic Chemistry
  • Inorganic Chemistry

Fingerprint Dive into the research topics of 'Alzheimer’s disease and specialized pro-resolving lipid mediators: Do MAR1, RVD1, and NPD1 show promise for prevention and treatment?'. Together they form a unique fingerprint.

  • Cite this